ZERCEPAC

This brand name is authorized in Austria, Cyprus, Estonia, Spain, Finland, France, Ireland, Lithuania, Netherlands, Poland, Romania, United Kingdom

Active ingredients

The drug ZERCEPAC contains one active pharmaceutical ingredient (API):

1 Trastuzumab UNII P188ANX8CK - TRASTUZUMAB

Trastuzumab is a recombinant humanised IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2). Τrastuzumab has been shown, in both in vitro assays and in animals, to inhibit the proliferation of human tumour cells that overexpress HER2. Read about Trastuzumab

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L01FD01	Trastuzumab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FD HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors
Discover more medicines within L01FD01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1824432, 1860768, 1860779
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1201456001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 198301, 552863, 573901
Country: FR	Base de données publique des médicaments	Identifier(s): 60924642
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 390570
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1090867, 1092422, 1092832
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 57991
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100439371, 100460496, 100460509
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W66849001, W67810001, W67811001